Loading...
OTCM
PFND
Market cap66kUSD
Jul 09, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-87.50%
Name

Pathfinder Cell Therapy Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
-100.00%
1,201,00058,00035,0000000142,000134,000181,000360,000344,00073,000114,00054,0000
Net income
-2m
L-7.84%
-955,000-520,000-728,000-1,048,000-1,577,000-1,841,000-2,148,000-3,895,000-4,623,000-4,404,000-4,103,000-2,076,000-18,922,000-2,252,000-1,811,000-1,669,000
CFO
-963k
L-39.85%
-523,000-441,000-905,000-905,000-1,310,000-1,504,000-1,922,000-2,669,000-3,582,000-3,887,000-3,648,000-1,290,000-2,330,000-2,024,000-1,601,000-963,000

Profile

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
IPO date
Sep 22, 1992
Employees
Domiciled in
US
Incorporated in
US

Valuation

No data to show